home / stock / achv / achv news


ACHV News and Press, Achieve Life Sciences Inc. From 11/06/25

Stock Information

Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com

Menu

ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...

ACHV - Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ac...

ACHV - Expected US Company Earnings on Thursday, November 6th, 2025

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

ACHV - Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: AC...

ACHV - Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation...

ACHV - Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cess...

ACHV - Achieve: Expedited Review Of Cytisinicline Sets The Stage For Development Expansion

2025-10-20 07:15:34 ET The last time I wrote about Achieve Life Sciences (ACHV), it was with respect to a Seeking Alpha article entitled " Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement ". At that time, I had rated it as a "Buy" rating, and I'm going...

ACHV - US Companies Moving the Markets, Evening edition
Fri, Oct 17, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Rani Therapeutics Holdings Inc. (RANI) rose 248.3% to $1.64 on volume of 482,613,416 shares Beyond Meat Inc. (BYND) rose 24.2% to $0.6456 on volume of 419,584,353 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.0% to $4...

ACHV - US Companies Moving the Markets, Morning edition
Fri, Oct 17, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States Rani Therapeutics Holdings Inc. (RANI) rose 158.0% to $1.215 on volume of 150,083,425 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 3.9% to $4.175 on volume of 72,025,447 shares Bitfarms Ltd. (BITF) fell 8.5% to $4.83 o...

ACHV - Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (...

ACHV - Achieve, Disc, Revolution among winners of initial FDA national priority vouchers

2025-10-17 07:12:04 ET More on Regeneron, Achieve Life Sciences, etc. Regeneron: Growth Catalysts Incoming Achieve Life Sciences: Promising Pipeline But High Risks Makes Me Hold For Now Regeneron: Strong R&D Pipeline Drives Growth Outlook Regeneron gets F...

Previous 10 Next 10